Irinotecan, Cisplatin, and Etoposide for Small-Cell Lung Cancer
Author Information
Author(s): Sekine I, Nokihara H, Takeda K, Nishiwaki Y, Nakagawa K, Isobe H, Mori K, Matsui K, Saijo N, Tamura T
Primary Institution: National Cancer Center Hospital, Tokyo, Japan
Hypothesis
The study aims to evaluate the toxicities and antitumor effects of irinotecan plus cisplatin versus irinotecan, cisplatin, and etoposide in patients with extensive-disease small-cell lung cancer.
Conclusion
The IPE regimen was marginally more effective than the IP regimen but was too toxic despite G-CSF support.
Supporting Evidence
- The IPE regimen showed a promising response rate of 87%.
- The median progression-free survival was 5.4 months for the IPE arm.
- Grade 3 febrile neutropenia occurred in 31% of patients in the IPE arm.
Takeaway
Doctors tested two combinations of cancer drugs to see which worked better for patients with a serious type of lung cancer. One combination worked a little better but made patients feel much worse.
Methodology
Patients were randomly assigned to receive either irinotecan and cisplatin or irinotecan, cisplatin, and etoposide every 3 weeks for four cycles.
Limitations
The study had a small sample size and was limited to patients with extensive-disease small-cell lung cancer.
Participant Demographics
Patients aged 20 to 70 years with previously untreated extensive-disease small-cell lung cancer.
Statistical Information
P-Value
0.002
Confidence Interval
95% CI, 4.0–5.6
Statistical Significance
p=0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website